Northwest Biotherapeutics (NWBO) Price & Analysis

Q: What was Northwest Biotherapeutics’s price range in the past 12 months?

Northwest Biotherapeutics lowest stock price was $0.14 and its highest was $0.37 in the past 12 months.

Q: What is Northwest Biotherapeutics’s market cap?

Northwest Biotherapeutics’s market cap is $273.47M.

Q: When is Northwest Biotherapeutics’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

Q: How were Northwest Biotherapeutics’s earnings last quarter?

Northwest Biotherapeutics released its earnings results on May 16, 2018. The company reported -$0.089 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.089.

Q: Is Northwest Biotherapeutics overvalued?

According to Wall Street analysts Northwest Biotherapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Northwest Biotherapeutics pay dividends?

Northwest Biotherapeutics does not currently pay dividends.

Q: What is Northwest Biotherapeutics’s EPS estimate?

Northwest Biotherapeutics’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Northwest Biotherapeutics have?

Northwest Biotherapeutics has 1,688,074,500 shares outstanding.

Q: What happened to Northwest Biotherapeutics’s price movement after its last earnings report?

Northwest Biotherapeutics reported an EPS of -$0.089 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.

Q: Which hedge fund is a major shareholder of Northwest Biotherapeutics?

Currently, no hedge funds are holding shares in NWBO

545 Followers

NWBO Stock Chart & Stats

$0.17

<$0.01(1.12%)

At close: Jul 27 4:00 PM EDT

$0.17

<$0.01(1.12%)

Day’s Range― - ―

52-Week Range$0.14 - $0.37

Previous CloseN/A

Volume1.71M

Average Volume (3M)3.39M

Market Cap

$273.47M

Enterprise Value$374.52M

Total Cash (Recent Filing)$1.79M

Total Debt (Recent Filing)$63.99M

Price to Earnings (P/E)―

Beta1.04

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding1,688,074,500

10 Day Avg. Volume4,114,978

30 Day Avg. Volume3,387,030

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)-6.97

Price to Sales (P/S)240.49

P/FCF Ratio-7.16

Enterprise Value/Market Cap1.37

Enterprise Value/Revenue250.18

Enterprise Value/Gross Profit-557.33

Enterprise Value/Ebitda-6.26

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Northwest Biotherapeutics News

Northwest Biotherapeutics Secures New Convertible Note Financing

Northwest Biotherapeutics ( ($NWBO) ) has provided an update. On July 29, 2026, Northwest Biotherapeutics entered into a...

10h ago

NWBO

Northwest Biotherapeutics names Annalisa Jenkins as strategic advisor

Northwest Biotherapeutics (NWBO) announced the appointment of Annalisa Jenkins, M.B.B.S., F.R.C.P., as a Strategic Adviser. Dr. Jenkins brings...

3M ago

NWBO

Northwest Biotherapeutics establishes dedicated leukapheresis clinic

Northwest Biotherapeutics (NWBO) is establishing its own dedicated clinic for leukapheresis procedures at The London Welbeck Hospital. The...

3M ago

NWBO

Northwest Biotherapeutics Completes Advent BioServices Acquisition Deal

Northwest Biotherapeutics ( ($NWBO) ) has shared an update. On October 24, 2025, Northwest Biotherapeutics, Inc. completed the...

4M ago

NWBO

Northwest Biotherapeutics Delays Annual SEC Filing

Northwest Biotherapeutics ( ($NWBO) ) has released a notification of late filing. Northwest Biotherapeutics, Inc. has filed a...

4M ago

NWBO

Northwest Biotherapeutics Reaches Settlement Over 2020 Stock Options

Northwest Biotherapeutics ( ($NWBO) ) has provided an update. On December 12, 2025, Northwest Biotherapeutics entered into a...

7M ago

NWBO

Northwest Biotherapeutics Expands Authorized Common Stock Capacity

Northwest Biotherapeutics ( ($NWBO) ) has issued an announcement. At its annual meeting of stockholders on December 29,...

7M ago

NWBO

Northwest Biotherapeutics Secures $5M Convertible Note Financing

Northwest Biotherapeutics ( ($NWBO) ) just unveiled an announcement. On November 14, 2025, Northwest Biotherapeutics entered into a...

8M ago

NWBO

Northwest Biotherapeutics Secures $5.5M Loan Agreement

Northwest Biotherapeutics ( ($NWBO) ) just unveiled an update. On October 27, 2025, Northwest Biotherapeutics, Inc. entered into...

9M ago

NWBO

Northwest Biotherapeutics Files New Form S-3 Registration

Northwest Biotherapeutics ( ($NWBO) ) has shared an announcement. On October 23, 2025, Northwest Biotherapeutics filed a new...

9M ago

NWBO

Northwest Biotherapeutics Settles Litigation Over Option Awards

Northwest Biotherapeutics ( ($NWBO) ) has shared an update. Northwest Biotherapeutics has reached a settlement agreement on October...

10M ago

NWBO

Northwest Biotherapeutics announces passing of general counsel Les Goldman

Northwest Biotherapeutics (NWBO) announced the passing of its Senior Vice President and General Counsel, Les Goldman, due to...

12M ago

NWBO

Northwest Biotherapeutics Addresses Market Rumor Concerns

An update from Northwest Biotherapeutics (NWBO) is now available. NWBio has noticed a surge in shareholder inquiries concerning...

2y ago

NWBO

Northwest Biotherapeutics announces exclusive license from Roswell Park

Northwest Biotherapeutics announced that on June 12, 2024 it entered into an exclusive license from Roswell Park Comprehensive...

2y ago

NWBO

NWBO FAQ

What was Northwest Biotherapeutics’s price range in the past 12 months?

Northwest Biotherapeutics lowest stock price was $0.14 and its highest was $0.37 in the past 12 months.

What is Northwest Biotherapeutics’s market cap?

Northwest Biotherapeutics’s market cap is $273.47M.

When is Northwest Biotherapeutics’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Northwest Biotherapeutics’s earnings last quarter?

Northwest Biotherapeutics released its earnings results on May 16, 2018. The company reported -$0.089 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.089.

Is Northwest Biotherapeutics overvalued?

According to Wall Street analysts Northwest Biotherapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Northwest Biotherapeutics pay dividends?

Northwest Biotherapeutics does not currently pay dividends.

What is Northwest Biotherapeutics’s EPS estimate?

Northwest Biotherapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Northwest Biotherapeutics have?

Northwest Biotherapeutics has 1,688,074,500 shares outstanding.

What happened to Northwest Biotherapeutics’s price movement after its last earnings report?

Northwest Biotherapeutics reported an EPS of -$0.089 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.

Which hedge fund is a major shareholder of Northwest Biotherapeutics?

Currently, no hedge funds are holding shares in NWBO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Northwest Biotherapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

190.49%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Northwest Biotherapeutics

Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology firm that creates personalized immune-based treatments for various cancers, operating both within the United States and internationally. Their product pipeline relies on DCVax, a proprietary technology platform. This platform harnesses a patient's own activated dendritic cells to stimulate their immune system to combat cancerous cells. The company's leading therapeutic candidate, DCVax-L, has successfully completed Phase III clinical trials targeting Glioblastoma multiforme, an aggressive form of brain cancer. Additionally, Northwest Biotherapeutics is progressing DCVax-Direct through Phase I/II clinical studies, focusing on the treatment of inoperable solid tumors. Founded in 1996, the company's headquarters are situated in Bethesda, Maryland.